Nature of the Event

GlaxoSmithKline Pharmaceuticals Limited conducted its Q2 FY27 Earnings Conference Call on November 04, 2026, following the board meeting on November 03, 2026. The call was moderated by Dorwin Dias from Chorus Call, with participation from Managing Director Mr. Bhushan Akshikar and CFO Mr. Ronojit Biswas.

Financial Performance Summary

Revenue Performance:

  • Q2 FY27 revenue increased 21% year-over-year to INR1,180 crore, representing the company's highest quarterly sales
  • Underlying growth excluding tailwinds (low base effect from CMO fire and GST 2.0 impact) was 12-13%
  • Volume growth in established products business was mid to high single-digit (5-7%)

Profitability Metrics:

  • EBITDA grew 20% to INR400 crore with margins maintained at 34%
  • Underlying EBITDA growth excluding tailwinds was approximately 13%
  • PAT increased 33% to INR19.76 earnings per share
  • One-time benefit of INR42 crore from income tax refund with interest component included in PAT
  • Without this benefit, underlying PAT growth would have been 21% in line with sales growth

Balance Sheet & Cash Flow:

  • Company remains zero debt with INR2,200 crore cash on balance sheet
  • Cash conversion ratio running at 98%
  • Strong working capital management maintained

Half-Year Performance (H1 FY27):

  • Revenue growth: 18%
  • EBITDA growth: 18%
  • PAT growth: 29%

Business Segment Performance

Portfolio Transformation:

  • Innovation portfolio (oncology, adult vaccines, specialty respiratory) now contributes 7% to overall revenues, up from 3% same quarter last year
  • Innovation portfolio contributes one-quarter of overall growth
  • Established products business (general medicines, paediatric vaccines) showing strong volume growth

Therapeutic Area Performance:

  • General Medicines: All flagship brands delivered evolution index above 100%, gaining market share
  • Paediatric Vaccines: Maintained leadership position in self-pay private market, gained market share in flagship brands
  • Adult Vaccines: Shingrix sales doubled year-over-year
  • Oncology: Impacted approximately 300 patients quarterly with Jemperli and Zejula assets

Gross Margin Pressures

  • Gross margins declined approximately 120 basis points due to:
  • Rupee appreciation impact
  • Oil-linked inflation on raw materials (APIs, packaging materials)
  • Company implementing cost mitigation measures including competitive price increases
  • Adverse gross margin impact offset by improved spend ratio (1 percentage point improvement)

Strategic Priorities & Outlook

Growth Strategy:

  • Three core priorities: relentless top-line growth, accelerating new launches, simplifying operations
  • Targeting revenue doubling to INR8,000 crore by 2031
  • Growth composition: 60% from established products organically, 40% from new pipeline launches
  • Established products expected to deliver high single-digit growth

Pipeline Developments:

  • Blenrep launch scheduled for Q3 FY27 in multiple myeloma (hematological malignancies)
  • Over 30 global clinical trials (Phase 3A, 3B) ongoing in India across oncology indications
  • Hibsago (Bepirovirsen) for chronic hepatitis B functional cure - regulatory applications pending for India launch

Margin Outlook:

  • Company expects to maintain current margin profile (34% EBITDA)
  • Priority remains top-line growth and gross margin expansion
  • EBITDA margin viewed as outcome rather than primary target

Regulatory Environment & Pricing

  • Management addressed concerns about oncology drug pricing regulations
  • Company operates within 30% trade margin guardrails established by regulators
  • India-specific tiered pricing model already in place for all launches
  • Recent trade margin rationalization measures have not impacted company's pricing or margins
  • All future launches will adhere to regulatory pricing frameworks

Operational Updates

  • Calpol brand recovered strongly with evolution index of 112% and internal growth of 30-35% in Q2
  • Supply chain disruptions from previous year fully resolved
  • Specialty businesses operate with dedicated teams: oncology has ~50 specialized personnel
  • Each specialty business unit (oncology, respiratory, hepatology) has separate commercial teams

Q&A Highlights

  • Management confirmed input cost pressures primarily oil-related and forex-driven, not API-specific
  • Company maintains focus on top-line growth while managing margin structure
  • Specialty portfolio expansion requires specialized commercial teams rather than shared resources
  • Double-digit growth expected to continue in H2 FY27 driven by base business recovery and new launches